Prosecution Insights
Prosecution Insights
11 pending office actions • 7 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (45%) |
| §102 only | 1 (9%) |
| No statute on record | 5 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALSOMAIRY, SARAH ABDOALATIF | 2 | 60.1% | +25.4% |
| BORGEEST, CHRISTINA M | 1 | 55.4% | +22.1% |
| LU, CHENG | 1 | 54.1% | +67.9% |
| BELYAVSKYI, MICHAIL A | 1 | 63.8% | +27.5% |
| DUNN, MCKENZIE A | 1 | 57.1% | +50.2% |
| DAUNER, JOSEPH G | 1 | 56.8% | +34.8% |
| XIAO, YAN | 1 | 67.9% | +51.5% |
| VARMA, AKASH K | 1 | 65.7% | +34.8% |
| DONOGHUE, BRITTNEY ERIN | 1 | 59.8% | +55.2% |
| JOHANSEN, PETER N. | 1 | 60.0% | +23.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17775492 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DONOGHUE, BRITTNEY ERIN | 89d overdue |
| 17786107 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY QUANTIFICATION OF EXCIPIENTS | VARMA, AKASH K | 79d overdue |
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | ALSOMAIRY, SARAH ABDOALATIF | 72d overdue |
| 18192286 | UVEAL MELANOMA TREATMENT USING SEA-CD40 | DUNN, MCKENZIE A | 70d overdue |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | XIAO, YAN | 43d overdue |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | ALSOMAIRY, SARAH ABDOALATIF | 30d overdue |
| 16589914 | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy | JOHANSEN, PETER N. | 17d overdue |
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 9d overdue |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1642 | 2 |
| 1644 | 2 |
| 1646 | 2 |
| 1678 | 1 |
| 1682 | 1 |
| 1773 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18334680 | Glycan-Interacting Compounds and Methods of Use | BORGEEST, CHRISTINA M | 1675 | Other | Non-Final OA | 13d | Pending | Jun 14, 2023 |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 1642 | Other | Non-Final OA | 46d | Pending | May 30, 2023 |
| 18030225 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | BELYAVSKYI, MICHAIL A | 1644 | §103 | Non-Final OA | — | Pending | Apr 04, 2023 |
| 18192286 | UVEAL MELANOMA TREATMENT USING SEA-CD40 | DUNN, MCKENZIE A | 1678 | Other | Non-Final OA | 70d overdue | Pending | Mar 29, 2023 |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | 30d overdue | Pending | Jan 25, 2023 |
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 1682 | §103 | Non-Final OA | 9d overdue | Pending | Dec 16, 2022 |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | XIAO, YAN | 1642 | §103 | Non-Final OA | 43d overdue | Pending | Nov 18, 2022 |
| 17786107 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY QUANTIFICATION OF EXCIPIENTS | VARMA, AKASH K | 1773 | §103 | Non-Final OA | 79d overdue | Pending | Jun 16, 2022 |
| 17775492 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DONOGHUE, BRITTNEY ERIN | 1675 | §102 | Non-Final OA | 89d overdue | Pending | May 09, 2022 |
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Other | Non-Final OA | 72d overdue | Pending | Mar 23, 2022 |
| 16589914 | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy | JOHANSEN, PETER N. | 1644 | Other | Final Rejection | 17d overdue | Pending | Oct 01, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial